BioVector? WM88 人皮膚黑色素瘤細(xì)胞系 / BioVector? WM88 Human Skin Melanoma Cell Line

通用定義 / General Definition:BioVector? WM88 是一種源自人皮膚黑色素瘤 (Melanoma) 的原發(fā)性腫瘤細(xì)胞系。該細(xì)胞系處于黑色素瘤發(fā)展的垂直生長期 (Vertical Growth Phase, VGP)。在臨床分期上，VGP 標(biāo)志著腫瘤開始具備侵襲真皮層并獲得轉(zhuǎn)移潛能的關(guān)鍵階段。WM88 攜帶黑色素瘤中最常見的 BRAF V600E 突變，使其成為研究 MAPK 信號通路傳導(dǎo)、黑色素瘤侵襲機(jī)制以及評估 BRAF 抑制劑（如威羅菲尼）藥效的重要實驗?zāi)Ｐ汀?/p>

BioVector? WM88 is a human skin Melanoma cell line derived from a primary tumor. It represents the Vertical Growth Phase (VGP) of melanoma development. Clinically, the VGP marks the critical transition where the tumor gains the ability to invade the dermis and acquires metastatic potential. WM88 carries the highly prevalent BRAF V600E mutation, making it an essential experimental model for studying MAPK signaling pathways, melanoma invasion mechanisms, and evaluating the efficacy of BRAF inhibitors (e.g., Vemurafenib).

BioVector? WM88 技術(shù)說明書 (Technical Datasheet)

中文版說明書 (Chinese Datasheet)

1. 產(chǎn)品基本信息

• 產(chǎn)品名稱： BioVector? WM88 人皮膚黑色素瘤細(xì)胞

• 組織來源： 皮膚 (Skin)

• 疾病背景： 黑色素瘤 (原發(fā)灶，垂直生長期)

• 生長特性： 貼壁生長

• 細(xì)胞形態(tài)： 紡錘形或多角形，呈現(xiàn)黑色素瘤細(xì)胞典型的異質(zhì)性。

2. 培養(yǎng)條件

• 基礎(chǔ)培養(yǎng)基： BioVector? W489 培養(yǎng)基 或 MCDB153/L15 (4:1) 混合培養(yǎng)基（含 2mM L-谷氨酰胺）。

• 血清添加： 2% - 5% BioVector? 優(yōu)質(zhì)胎牛血清 (FBS)。

• 關(guān)鍵添加劑： 某些方案可能建議添加胰島素。

• 培養(yǎng)環(huán)境： 37 攝氏度，5% CO2

• 傳代比例： 1:2 至 1:4；建議在細(xì)胞匯合度達(dá)到 80%-90% 時進(jìn)行傳代。

3. 細(xì)胞應(yīng)用

• 信號傳導(dǎo)研究： 研究 BRAF V600E 突變驅(qū)動的下游 MAPK/ERK 通路活化。

• 侵襲與遷移： 評估黑色素瘤細(xì)胞從原發(fā)灶向深層組織浸潤的動力學(xué)。

• 耐藥性建模： 建立針對 BRAF/MEK 抑制劑的獲得性耐藥模型。

4. 注意事項

• 基因型驗證： 鑒于黑色素瘤細(xì)胞的高度異質(zhì)性，建議定期驗證其 BRAF 突變狀態(tài)。

• 生長速度： VGP 期的細(xì)胞通常比早期 RGP（徑向生長期）細(xì)胞生長更快，需注意控制傳代密度。

English Datasheet

1. General Product Information

• Product Name: BioVector? WM88 Human Skin Melanoma Cell Line

• Tissue Source: Skin

• Disease Context: Melanoma (Primary tumor, Vertical Growth Phase)

• Growth Properties: Adherent

• Morphology: Spindle-shaped or polygonal, showing characteristic melanoma cell heterogeneity.

2. Culture Conditions

• Basal Medium: BioVector? W489 Medium or a mixture of MCDB153 and L15 (4:1) supplemented with 2mM L-Glutamine.

• Serum Supplement: 2% - 5% BioVector? Fetal Bovine Serum (FBS).

• Supplements: Some protocols recommend the addition of insulin for optimal maintenance.

• Incubation: 37 degrees Celsius, 5% CO2

• Subculturing: 1:2 to 1:4 ratio; subculture when cells reach 80%-90% confluence.

3. Applications

• Signal Transduction: Investigating the activation of the MAPK/ERK pathway driven by the BRAF V600E mutation.

• Invasion and Migration: Assessing the kinetics of melanoma infiltration from the primary site into deeper dermal layers.

• Drug Resistance Modeling: Developing models for acquired resistance against BRAF or MEK inhibitors.

4. Key Usage Notes

• Genotype Authentication: Given the high heterogeneity of melanoma lines, periodic verification of the BRAF V600E mutation status is strongly recommended.

• Growth Management: VGP stage cells typically proliferate more rapidly than earlier RGP (Radial Growth Phase) cells; maintain a consistent subculturing schedule to prevent over-confluence.

注意 / Note: BioVector? WM88 應(yīng)在生物安全二級 (BSL-2) 條件下操作。為保持其侵襲表型，建議使用較低百分比的血清和專門優(yōu)化的黑色素瘤培養(yǎng)基。BioVector? WM88 should be handled under Biosafety Level 2 (BSL-2) conditions. To maintain its invasive phenotype, BioVector? recommends using low-serum concentrations and specialized, optimized melanoma media formulations.

BioVector NTCC質(zhì)粒載體菌株細(xì)胞蛋白抗體基因保藏中心

E-mail: [email protected]

http://www.nedfriskphoto.com